Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New scan could sharpen ovarian cancer detection

NCT ID NCT05903807

First seen May 29, 2026 · Last updated Jun 19, 2026 · Updated 4 times

Summary

This study tested whether a new radioactive tracer called FAPI-46, used with a PET/CT scan, can more accurately detect the spread of ovarian cancer compared to standard scans. Researchers planned to enroll 50 women with newly diagnosed ovarian cancer, but the study was terminated early. If the tracer proves effective, it could help doctors stage the cancer more precisely and tailor treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Aalborg University Hospital

    Aalborg, North Denmark, 9000, Denmark

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

68Ga-FAPI-46 (a radioactive tracer for PET scans)

What this could lead to

If successful, this could provide a more accurate way to stage ovarian cancer, helping doctors choose the best treatment plan.

What could go wrong

This is a small, early-phase study that was terminated, so results are limited. The tracer may not prove more accurate than existing methods.

Conditions

The condition(s) this trial relates to.

neoplasm ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.